CTOs on the Move

Audentes Therapeutics

www.audentestx.com

 
Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities.
  • Number of Employees: 100-250
  • Annual Revenue: $500M-1 Billion
  • www.audentestx.com
  • 600 California Street 17th Floor
    San Francisco, CA USA 94108
  • Phone: 415.638.6556

Executives

Name Title Contact Details
John Gray
Senior Vice President and Chief Technology Officer Profile

Funding

Audentes Therapeutics raised $137.5M on 10/13/2015

Similar Companies

Axovant

Axovant Sciences is a leading clinical-stage neurology company focused on the treatment of dementia and related neurological disorders. We aspire to lead the way into a new era of progress to protect the fullness of life for people living with neurologic conditions. We see the potential of compelling therapeutic pathways and set our sights high on creating life-changing advancement for millions of people affected by neurologic disorders.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Progressive Medical

Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Symic Biomedical

Symic is developing a new category of therapeutics that offer an exciting and biologically innovative approach to treating disease. While it is clear that cells play an important role in tissue inflammation and regeneration, it is also known that the extracellular matrix (ECM) plays an equally critical role in maintaining healthy tissue. The ECM is the non-cellular component of the body’s tissues, and proteoglycans are important structural and functional macromolecules native to the ECM that are known to protect against tissue degradation and promote healing during illness or injury. Recognizing the importance of proteoglycans in many acute and chronic disease states, Symic developed a library of proprietary, ECM-specific compounds that mimic the protective effect of natural proteoglycans. For controlled injuries (e.g. incisions, balloon angioplasty), Symic’s ECM-specific compounds allow for local application, enhancing their ability to attenuate inflammation and reduce scarring only at the site of injury. In disease states known for chronic inflammation involving the ECM (e.g. cartilage in osteoarthritis), Symic’s technology can disrupt the cycle of degradation-inflammation by directly targeting and protecting the injured ECM. The ECM plays a critical role in many acute and chronic disease states, many of which have limited or no effective therapeutic options. Symic plans to advance its compounds in a variety of therapeutic areas with unmet clinical needs.

Suncoast Perfusion Services

Suncoast Perfusion Services is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.